Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H-3-2011-088 | Other Identifier | The Danish National Committee for Research Ethics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Diabetes(both types) are recognized by high levels of glucagon in the circulation.
Glucagon is known to increase blood glucose, and might therefore contribute to the respective diseases. Under some circumstances the gut hormone GLP-1 inhibits the glucagon secretion.
The investigators aim to identify the impact of GLP-1 on the glucagon secretion, at increasing blood glucose levels in healthy subjects, in patients with type 2 diabetes, and in patients with type 1 diabetes.
The investigators think that the effect of GLP-1 on the glucagon secretion might be dependent of blood glucose levels.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Subjects | Other |
| |
| T2DM | Other |
| |
| T1DM | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Native human Glucagon-like Peptide-1 ( GLP-1(7-36)) | Drug | Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step) |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma Glucagon response to the GLP-1 infusion / glucose clamp | The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session | At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| Plasma GLP-1 response to the GLP-1 infusion / glucose clamp | The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session | At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| Plasma Glucose response to the GLP-1 infusion / glucose clamp | The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session | At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| Measure | Description | Time Frame |
|---|---|---|
| Resting Metabolic Rate response to the GLP-1 infusion / glucose clamp | Assessed by indirect calorimetry during the GLP-1 infusion / glucose clamp-session | at 0, 120, and 180 min |
| Hunger scores response to the GLP-1 infusion / glucose clamp |
Not provided
Inclusion Criteria:
Patients with T2DM
Exclusion Criteria:
Patients with T2DM
Healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gentofte University Hospital | Hellerup | DK-2900 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33722838 | Derived | Bagger JI, Grondahl MFG, Lund A, Holst JJ, Vilsboll T, Knop FK. Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. Diabetes. 2021 Jun;70(6):1347-1356. doi: 10.2337/db20-0998. Epub 2021 Mar 15. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C061970 | glucagon-like peptide 1 (7-36) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| NaCl | Drug | Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step) |
|
| Native human Glucagon-like Peptide-1 ( GLP-1(7-36)) | Drug | Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step) |
|
| Native human Glucagon-like Peptide-1 ( GLP-1(7-36)) | Drug | Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step) |
|
Assessed by VAS during the 210 min GLP-1 infusion / glucose clamp-session
| At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| plasma Insulin response to the GLP-1 infusion / glucose clamp | The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session | At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| plasma GIP response to the GLP-1 infusion / glucose clamp | The collection of blood samples will be done during the 210 min GLP-1 infusion / glucose clamp-session | At 0, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195, 210 min |
| Food Intake | Assessed by ad'libitum meal after the 210 min GLP-1 infusion / glucose clamp. | at 210 min |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |